# Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results

- Source: PR Newswire M&A
- Published: 2026-11-02T21:49:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/neurocrine-biosciences-reports-third-quarter-2026-financial-results-302926995.html
- Canonical: https://groundlevelnews.com/story/neurocrine-biosciences-reports-third-quarter-2026-financial-results-ceb0fb/

Total Third-Quarter 2026 Revenue Grew 41% Year-Over-Year to $1.1 Billion INGREZZA® (valbenazine) 2026 Net Sales Guidance Raised to $2.9 to $2.925 Billion SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._